- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
More ▼
Key statistics
On Friday, XOMA Corp (XOMA:NMQ) closed at 24.78, -8.22% below its 52-week high of 27.00, set on Apr 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.58 |
---|---|
High | 25.58 |
Low | 24.60 |
Bid | 23.00 |
Offer | 26.50 |
Previous close | 25.44 |
Average volume | 9.78k |
---|---|
Shares outstanding | 11.64m |
Free float | 11.59m |
P/E (TTM) | -- |
Market cap | 288.32m USD |
EPS (TTM) | -4.04 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼